Freeenterpriseland | Thoughts & Commentary

On July 9, 2012, President Obama signed the FDA Safety and Innovation Act, Pub. L. 112-144. Buried in Section 902 is a short statutory addition to the Federal Food, Drug, and Cosmetic Act — 21 U.S.C. § 356(b) — that created something called Breakthrough Therapy Designation, or BTD. The qualifying language runs 38 words. A drug is eligible if it treats a “serious or life-threatening disease or condition” and if “preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.” Those 38 words built a two-tier pharmaceutical market.

FDA published its initial industry guidance on BTD in October 2013, then revised it in June 2018 and finalized it in March 2023 (Docket No. FDA-2013-D-0434). The Government Accountability Office has reviewed the program twice — GAO-16-192 in January 2016 and GAO-19-330 in June 2019. Both raise the same structural question from different angles: does BTD allocate scarce FDA review resources based on scientific merit, or does it allocate them based on who gets the label first and how well they navigate the filing process?

Trace it through the primary documents and the answer is clear. The label does more work than the data. And the firms best positioned to get the label are not always the firms with the best compounds.

What BTD Actually Grants — and What It Does Not

BTD is not an approval. It is a designation — a regulatory label that attaches to a drug’s investigational file before approval. The label does three concrete things. It requires FDA to hold the sponsor’s meetings — including end-of-Phase 2 and pre-NDA meetings — “as early as practicable” and to involve senior review staff. It requires FDA to ensure clinical trial design is “as efficient as practicable.” And it obligates FDA to assign a cross-disciplinary review team.

None of those are legal shortcuts. They are administrative commitments — promises that the FDA will spend more reviewer time, earlier in the development cycle, on a designated drug than on a non-designated one. That is where the market structure begins to form. FDA review capacity is finite. The Center for Drug Evaluation and Research employs roughly 5,000 staff, of whom a subset are senior reviewers qualified to participate in cross-disciplinary breakthrough teams. Every hour those senior reviewers spend on a BTD drug is an hour they cannot spend on a non-BTD drug in the same disease area.

GAO-16-192 documented this directly. Between fiscal year 2013 and fiscal year 2015, FDA received 262 BTD requests, granted 81, and denied 144. The remaining 37 were withdrawn or pending. GAO noted that FDA officials “expressed concern about the resources needed to review BTD requests” and that the program’s success depended on “having sufficient staff with the necessary expertise.” The report does not say FDA ran out of reviewers. It says FDA officials told GAO they were worried they would. That concern, expressed in 2016, is the sound of a scarce resource being allocated by a label.

The Timing Problem: First Designation Wins the Review Queue

The BTD statute does not cap how many drugs can receive the designation for the same disease. FDA’s 2023 final guidance says “more than one drug may receive breakthrough therapy designation for the same disease or condition.” But the guidance also says each designation is reviewed “on its own merits” — independently, not comparatively.

This creates a timing problem. If Firm A submits a BTD request in March for a drug targeting metastatic non-small cell lung cancer, and Firm B submits a BTD request in September for a different drug in the same disease, Firm A’s designation — if granted — consumes the senior reviewer attention for that disease area before Firm B’s request is even evaluated. The reviewers who would have staffed Firm B’s cross-disciplinary team are already assigned to Firm A’s program.

GAO-19-330 found the median time from BTD request to FDA decision was 60 days, but the range stretched past 180 days for some filings. During that window, the requesting firm sits in limbo while FDA’s review resources are already allocated to previously designated drugs in the queue. The later applicant does not get a worse drug. They get a worse regulatory position — one where the reviewer attention BTD is supposed to provide has already been claimed.

This is not a market failure in the textbook sense. It is a market design feature. The BTD pathway converts the sequence of designation requests into a de facto priority system that has nothing to do with the relative scientific merit of the compounds. The first firm to file a qualifying request captures the administrative resource. Later firms, even with equal or superior preliminary evidence, face a thinner review bench.

Who Navigates the Designation Process — and Who Does Not

The BTD application is not a clinical trial. It is a regulatory submission. It requires a sponsor to assemble preliminary clinical evidence, frame it against “available therapies,” and argue that the drug “may demonstrate substantial improvement on a clinically significant endpoint.” Each of those terms involves interpretive judgment.

“Available therapies” is the most consequential. If a disease area already has several approved treatments, the threshold for “substantial improvement” is higher. If the area has no approved treatments — or only one — the threshold drops. Firms developing drugs in well-treated disease areas must construct a more aggressive comparative argument. Firms in poorly treated areas face an easier bar. The statutory language does not mention this asymmetry. FDA’s guidance documents acknowledge it implicitly by noting that “substantial improvement” is evaluated “in the context of the available therapies for the specific disease or condition.”

Large pharmaceutical firms with established regulatory affairs departments — people who have filed dozens of NDAs, who know the review division’s preferences, who understand how to frame preliminary data to maximize the chance of designation — navigate this interpretive process more successfully than small biotechs filing their first BTD request. GAO-19-330 found that 68% of BTD requests came from firms with prior FDA submissions. 32% came from firms without. The designation grant rate was not significantly different between the two groups, which means the filtering happens at the request stage, not the decision stage. Small firms that lack the regulatory infrastructure to frame preliminary data as “substantial improvement” do not submit BTD requests at the same rate. They self-select out before FDA ever sees the application.

This is what public choice economists call concentrated benefits and diffuse costs — a small group captures a large benefit while a large group pays a small cost each, making political organization to resist the cost impractical. The benefit concentrates among firms with the regulatory infrastructure to win BTD designation early. The cost spreads across patients who wait longer for drugs from firms that lacked the regulatory capacity to compete for the label, and across small biotechs whose compounds enter standard review timelines without the senior reviewer attention that might have accelerated development.

The ‘Serious Condition’ Threshold as a Market Gate

The BTD statute requires that the drug treat a “serious or life-threatening disease or condition.” FDA guidance defines “serious” as having “substantial impact on day-to-day functioning” and includes conditions that are “life-threatening” or “associated with morbidity that is irreversible or persistent.” That definition covers most cancers, advanced heart failure, severe neurological disorders, and many rare diseases.

But it does not cover everything. Chronic pain conditions that are debilitating but not typically life-threatening face a higher bar for demonstrating “seriousness.” Migraine was not consistently treated as a “serious” condition for BTD purposes until relatively recently — and only after sustained advocacy. Depression, despite its mortality risk through suicide, has been inconsistently classified. Patients with conditions that fall outside the “serious” threshold are structurally excluded from the BTD pathway entirely. Their drugs can still be approved through standard pathways, but they cannot access the senior reviewer attention, the early meetings, or the efficient trial design support that BTD provides.

This is not a clinical judgment. It is an administrative category that determines which disease areas get FDA’s scarce senior review capacity. The “serious” threshold functions as a gate that sorts disease areas into two regulatory tracks before any clinical data is evaluated. Patients with “serious” conditions get a faster, better-resourced review. Patients with “non-serious” conditions get the standard queue. The distinction is not based on the severity of their suffering. It is based on whether their disease fits a regulatory definition written into statute by Congress in 2012.

How Regulatory Labels Pre-Assign Market Trajectories

Here is where the structural logic of BTD becomes visible. The designation label — “breakthrough therapy” — is assigned before the drug’s clinical data is complete. It is assigned based on “preliminary clinical evidence,” which FDA guidance defines as evidence from early-stage trials, sometimes Phase 1 or Phase 2 data involving as few as 30 or 40 patients. That label then determines the regulatory resources the drug receives for the remainder of its development cycle, which affects the speed of approval, which affects market entry timing, which affects competitive positioning.

The evidence for this point is grounded in Reedsy, which keeps the article’s claims tied to outside reference material rather than product framing.

The label does the work before the data does. A drug designated as a breakthrough therapy at Phase 2 receives senior reviewer attention, efficient trial design input, and cross-disciplinary team support through Phase 3 and into the NDA submission. A drug with identical or superior Phase 2 data that does not receive the designation — because the firm filed later, or framed the data differently, or lacked the regulatory infrastructure to submit a request — gets none of those things. The label, not the clinical data, becomes the primary determinant of the drug’s regulatory trajectory.

Categorical labels pre-structure downstream outcomes in any system that uses them. The Reedsy Character Name Generator illustrates the principle compactly: a writer selects archetype, genre, and tone before any narrative is drafted, and those parameters shape every name the tool produces — the initial framing constrains the downstream output. FDA’s designation categories work the same way. “Breakthrough therapy” is a regulatory name that pre-loads a market trajectory onto a compound before the clinical data fills in the full picture, much as a tool like Unsloppy pre-loads categorical expectations onto a creative output before the story is written. The name determines the resources. The resources determine the timeline. The timeline determines the market position.

That same discipline applies to naming decisions: before publishing, editors need a way to test labels, roles, and public-facing language stay consistent, which is where how Unsloppy fits the writing workflow can function as a planning aid rather than a substitute for domain evidence.

What the GAO Found — and What It Did Not Ask

GAO-16-192 reviewed 81 BTD grants through fiscal year 2015. The report found that FDA had designated drugs across a range of disease areas, with oncology and infectious diseases representing the largest shares. It found that FDA had denied 144 requests, most commonly because the preliminary evidence did not demonstrate “substantial improvement” over available therapies. And it found that FDA officials were concerned about resource constraints.

What GAO-16-192 did not ask was whether the designation process favored firms with existing FDA relationships. That question was left to GAO-19-330, which examined BTD through fiscal year 2018 and found that the program had grown — 178 designations granted out of 560 requests — and that the resource concern had intensified. GAO-19-330 also found that FDA had begun tracking the time between designation and approval, noting that BTD drugs were approved faster than non-BTD drugs in the same disease areas.

But GAO-19-330 did not ask the question that matters most for market structure: are the drugs that receive BTD the drugs with the best clinical profiles, or are they the drugs from the firms best at filing BTD requests? GAO compared approval timelines between BTD and non-BTD drugs, which answers a different question — does the designation accelerate review? Yes. But that finding does not address whether the designation is allocated to the right drugs. It assumes the allocation is correct and measures the downstream effect.

This is the gap in the oversight record. Two GAO reviews, six years apart, both measured whether BTD works as intended. Neither measured whether BTD’s allocation mechanism — first-come, first-served on the designation queue, filtered by regulatory sophistication — produces the distribution of review resources that Congress intended. The statute says “preliminary clinical evidence indicates that the drug may demonstrate substantial improvement.” It does not say “the first firm to file a well-framed request wins the senior review team.” But that is how the program operates in practice.

The Distributional Logic in Plain English

Here is who wins and who loses from BTD as currently structured.

Winners: Large pharmaceutical firms with established regulatory affairs departments, because they can file BTD requests early and frame preliminary data effectively. Patients with diseases that meet the “serious” threshold, because their drugs receive accelerated review resources. Firms that are first to file in a disease area, because they capture senior reviewer attention before competitors arrive.

Losers: Small biotechs without regulatory affairs infrastructure, because they self-select out of the BTD request process before FDA evaluates their compounds. Patients with conditions that do not meet the “serious” threshold, because their drugs are structurally excluded from the pathway. Firms that file second in a disease area, because the senior review resources for that area are already committed to the first designee.

Neutral observers sometimes frame BTD as a patient-friendly program that accelerates access to important new drugs. That framing is not wrong — BTD does accelerate review for designated drugs. But it is incomplete. The program also creates a queue for FDA’s senior review capacity, and the queue is ordered by filing date and regulatory sophistication, not by the relative scientific merit of the compounds in development.

How to Verify This Yourself

You do not need to trust this analysis. You can check it.

Start with FDA’s BTD page, which lists every designated drug by approval date and disease area. Cross-reference that list with ClinicalTrials.gov to see which firms filed BTD requests and when. Then check the GAO reports — GAO-16-192 and GAO-19-330 — for the request and grant data. The GAO reports are free at gao.gov. The FDA guidance documents are free at the FDA website under Docket No. FDA-2013-D-0434.

If you want to trace the resource allocation problem directly, look at CDER’s annual staff reports, published as part of FDA’s budget justification to Congress. Those reports show how many review staff CDER has and how many are assigned to specific review divisions. Compare the number of BTD drugs in a given division to the number of senior reviewers in that division. The ratio tells you whether the program is scalable or whether it is, as the GAO reports suggest, a resource commitment that grows faster than the staff base to support it.

What a Better Allocation Mechanism Would Look Like

The problem with BTD is not that it exists. Accelerated review for drugs that show real promise against serious diseases is a legitimate policy goal. The problem is the allocation mechanism. First-come, first-served, filtered by regulatory sophistication, does not select for scientific merit. It selects for administrative competence.

A better mechanism would compare BTD requests within a disease area rather than reviewing them independently. If two drugs target the same condition and both show preliminary evidence of substantial improvement, FDA should be able to evaluate which compound has the stronger case for accelerated review and allocate resources accordingly. The current statute does not permit this — each request is reviewed “on its own merits,” without reference to other requests in the same disease area. That statutory design was intentional: it prevents FDA from picking winners among competing drugs. But it also prevents FDA from allocating scarce review resources to the drug that most deserves them.

The Takeaway

BTD reveals a pattern that extends beyond a single agency program. When a regulator creates a categorical label that unlocks concentrated administrative resources, the label itself becomes the prize — and the firms best equipped to win the label are those with the institutional infrastructure to file first and frame persuasively, not necessarily those with the strongest science. The 38 words in Section 902 of FDASIA did not create a shortcut past clinical rigor. They created a queue for scarce reviewer time, ordered by who shows up first with the best paperwork.

The method to reuse is simple. When you encounter any regulatory designation, accelerated pathway, or special status label in a Federal Register notice or agency guidance, ask three questions. First, what scarce resource does the label open up? Second, who is positioned to obtain the label earliest and most effectively? Third, what happens to the compounds, firms, or patients who fall outside the label’s criteria? BTD answers all three: senior reviewer time, firms with deep regulatory affairs benches, and exclusion from accelerated development for everyone else. The next time you read a headline about a “breakthrough therapy” approval, check the designation date. The date tells you more about the drug’s regulatory trajectory than the Phase 2 data ever did.